Previous 10 | Next 10 |
Analysis of data from Phase 3 studies in uUTI and cUTI to assess the relevance of a positive urine culture in patients with no clinical symptoms after being treated for a UTI New data on the efficacy of sulopenem in an animal model of anthrax DUBLIN, Ireland and CH...
DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by...
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both co...
Iterum Therapeutics ( NASDAQ: ITRM ) received a letter from Nasdaq that company has regained compliance with the minimum bid price requirement. Company was previously notified in September 2021 because its ordinary shares failed to meet the closing bid price of...
DUBLIN, Ireland and CHICAGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant path...
Iterum Therapeutics ( NASDAQ: ITRM ) shares dropped 12% pre-market on Wednesday in response to the firm's 1-for-15 reverse share split announcement. The drugmaker plans to implement the share split of its outstanding ordinary shares on Aug. 17, 2022, which will be effe...
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant patho...
Iterum Therapeutics press release ( NASDAQ: ITRM ): Q2 Non-GAAP EPS of -$0.03 beats by $0.03 . Cash, cash equivalents and short-term investments was $68.9 million at June 30, 2022 Shares +4% PM. For further details see: Iterum Therapeutics Non-GAAP EP...
--Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Iterum Therapeutics (NASDAQ: ITRM ) stock is taking off on Monday as investors react to news of a clinical trial agreement with the U.S. Food and Drug Administration (FDA). This agreemen...
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
Iterum Therapeutics plc Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...